Therapeutic efficiency of olaquindox in gamma-irradiated mice.
The antibacterial agent olaquindox (2-[N-(2-Hydroxy-ethyl)carbamoyl]-3-methyl-quinoxalin-1,4-dioxide) given in tap water at daily doses of 0.2 to 0.5 mg exerts beneficial effects on the body weight decrease and survival of gamma-irradiated mice. Beneficial effects are achieved especially by the postradiation administration of olaquindox. It is presumed that the mechanisms of the therapeutic effects of olaquindox are connected with its action on the composition of intestinal flora of mice.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003037:Cobalt Radioisotopes / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D007422:Intestines / Q000382:microbiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011810:Quinoxalines / Q000494:pharmacology / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000188:drug therapy* / Q000401:mortality; D014916:Whole-Body Irradiation
D000900:Anti-Bacterial Agents; D003037:Cobalt Radioisotopes; D011810:Quinoxalines; C013168:olaquindox